Animalcare Group has spent the past two years reshaping itself into a focused European veterinary pharmaceuticals business, culminating in a bolder push into equine medicine. Yet the question of what comes next has effectively been settled from the outside: on 16 April 2026 the board recommended a cash acquisition by Charterhouse Capital Partners at 336 pence a share, valuing the group at approximately £235.2m.

The Quick Version

  • Animalcare's board has recommended a 336p-per-share cash offer from Charterhouse's CCP Paw 2 Limited, valuing the group at roughly £235.2m; shareholders approved the scheme on 8 June 2026.
  • FY2025 revenue rose 20% to £89.1m and underlying EBITDA jumped 52.6% to £17.7m, with the January 2025 Randlab acquisition a major driver.
  • The equine franchise now accounts for roughly a quarter of group revenue after the AUD 120m Randlab deal, alongside companion-animal brands Daxocox, Plaqtiv+ and Orozyme.
  • Earlier disposals reshaped the group: Identicare (pet identification) was sold in February 2024, and a 33.34% stake in STEM Animal Health went to Dechra.
  • No final FY2025 dividend was proposed given the takeover; the AIM listing is expected to be cancelled around 31 July 2026, subject to court sanction.

What Animalcare Actually Sells

A York-based, commercial-stage animal-health company selling veterinary pharmaceuticals through veterinary channels — companion-animal medicines covering pain, dental care and dermatology, alongside a growing equine franchise and production-animal products. Following the January 2025 Randlab acquisition, its reach extends into Australia, New Zealand and the Middle East.

The Deal: 336p a Share, Approved and Moving Fast

On 16 April 2026, Animalcare's board agreed to a recommended acquisition by CCP Paw 2 Limited, a Charterhouse Capital Partners vehicle, at 336p in cash — a scheme of arrangement valuing the issued share capital at approximately £235.2m. Shareholders voted in favour on 8 June 2026, and a condition relating to Australia's Foreign Investment Review Board was subsequently satisfied. The court sanction hearing was scheduled for 28 July 2026, with the scheme expected effective 30 July 2026 and the AIM listing cancelled from 31 July 2026.

The Trading Behind the Takeover

For the year ended 31 December 2025, revenue was £89.1m, up 20.0% from £74.2m, with Randlab the principal driver alongside organic growth in flagship brands. Underlying EBITDA rose 52.6% to £17.7m, and the margin expanded to 20.6%. Underlying basic EPS increased 44.0% to 15.7p. Net debt (excluding IFRS 16) was £9.1m — leverage of about 0.7x underlying EBITDA following the debt-funded Randlab purchase.

The Randlab deal, completed 3 January 2025 for AUD 120m (around £62.2m), added an Australian equine pharmaceuticals specialist with subsidiaries in New Zealand and the Middle East, expected to be materially earnings-enhancing. A 25% stake in Australian companion-animal business InVetro followed in June 2025.

Portfolio Reshaping That Preceded the Deal

Animalcare's recent strategy involved disposing of non-core assets — Identicare (home to the Identichip brand), sold February 2024 for a reported £13.7m gain, and the STEM Animal Health stake, sold to Dechra for US$4.7m in April 2024 — while redeploying capital into higher-growth equine and companion-animal pharmaceuticals. R&D spending rose to around 4.5% of revenue.

What's Left for Shareholders to Weigh

With shareholder approval already secured, the practical questions for existing holders are narrow: the certainty and timing of completion, principally whether court sanction proceeds on the published timetable, and the mechanics of any reinvestment election for those wishing to roll over into the acquiring structure (deadline 21 July 2026).

Risks Worth Weighing

The principal near-term risk is transaction risk — schemes can, in rare cases, be delayed or fail to complete, in which case Animalcare would remain listed and its shares could re-rate lower. Beyond the deal, ordinary risks apply: dependence on a relatively small number of key brands, generic competition and pricing pressure, currency movements now amplified by Australian exposure following Randlab, and integration risk on acquisitions.

What to Watch Next

The court sanction hearing (28 July 2026), scheme effectiveness (30 July 2026) and AIM cancellation (from 31 July 2026). Delivery of the court order and payment of cash consideration would mark completion.